A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
Niharika B MettuDonna NiedzwieckiChristel RushingAndrew B NixonJingquan JiaSherri HaleyWanda HoneycuttHerbert HurwitzJohanna C BendellHope UronisPublished in: Cancer chemotherapy and pharmacology (2019)
The MTD/RPTD of GD is gemcitabine 1000 mg/m2 weekly for 3 of 4 weeks and dasatinib 50 mg PO BID. The clinical activity of GD seen in this study was modest, and does not support its further investigation in pancreatic cancer.